Activity Overview
The Lung Cancer Clinical Masterclass will comprise of 13-monthly episodes. Each episode will be led by two faculty presenters who will each deliver a 15-minute presentation, followed by a group discussion with the co-chairs.
The masterclass will examine the screening and diagnosis of early-stage lung cancer, investigate different histological techniques and the use of genomics for improved detection, classification, and monitoring. The series will also feature discussions around oncogenic driver mutations and their potential as targets for the development of molecular treatments. Existing and new treatment strategies will be appraised including research and developments in surgery, immunotherapy, chemotherapy, and radiation therapy in lung cancer in general and more specifically in non-small cell lung cancer (NSCLC). The last episode will discuss the management of mesothelioma.
Participants will not be able to claim credit until they have completed all masterclass videos and tests.
Target Audience
This initiative is intended for physicians, including lung oncologist, pulmonologist, thoracic surgeon, physician assistants, nurses, nurse practitioners, pharmacists, fellows/residents and other healthcare professionals with special interests in lung cancer.
- Examine the pathway for the diagnosis and screening of SCLC and NSCLC
- Discuss the role of novel therapies and treatment regimens in the management of lung cancer including:
- The translation of data from the study of specific genes into potential novel treatment regimens such as EGFR, KRAS, ALK, ROS-1, NTRK, RET and MET
- The development of new therapies and best practices in the management of first-line and second-line treatment
- Review effective radiotherapy schedules to improve patient outcomes
- Review surgically resectable disease in the neo-adjuvant and peri-operative setting
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. Claim credit will open August 2025. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Clinical CME Group, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 13 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 13 ANCC contact hours.
Pharmacists
Physician Associate
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Clinical CME Group, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 13 contact hour(s) (which includes 9 hour(s) of pharmacology).
Education Grants
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Hossein Borghaei DO, MS, discloses the following financial relationships: Advisor – BMS, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Puma, BerGenBio, Bayer, Iobiotech, Grid Therapeutics, RAPT; Consultant – BMS, Gilead, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Puma, BerGenBio, Bayer, Iobiotech, Grid Therapeutics, RAPT; Individual stocks and stock options – Sonnetbio (Stock Options), Inspirna (formerly Rgenix, Stock Options), Nucleai (stock options); Researcher – BMS, Lilly, Amgen; Data and Safety Monitoring Board: University of Pennsylvania: CAR T Program, Takeda, Incyte, Novartis, Springworks, Honoraria: Amgen, Pfizer, Daiichi, Regeneron Travel: Amgen, BMS, Merck, Lilly, EMD-Serono , Genentech, Regeneron, Mirati.
Jessica Donington, MD, discloses the following financial relationships: Advisor- AMGEN, AstraZeneca, Bristol Myers Squibb, Merck & Co., Inc., Genentech, Inc.; Speaker – AstraZeneca, Bristol Myers Squibb, Genentech, Inc.
Patrick Forde, MD PhD, discloses the following financial relationships: Research grants to Institution: AstraZeneca, BMS, Novartis, Regeneron, BioNTech; Consultant: Ascendis, AstraZeneca, BMS, Curevac, Novartis, Regeneron, G1, Genelux, Genentech, Gritstone, Merck, Janssen, F Star, Sanofi, Amgen, Fosun, Teva, Synthekine, Flame, Iteos, Tavotek, Teva.
Ticiana Leal, MD, discloses the following financial relationships: Advisor – Novocure, OncoC4, AstraZeneca; Consultant- Novocure, Roche/Genentech, Pfizer, Janssen, AbbVie, Gilead, Boehringer-Ingelheim, Lilly.
Stephen Liu, MD, discloses the following financial relationships: Consultant – Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Candel Therapeutics, Catalyst, Daiichi Sankyo, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, OSE Immunotherapeutics, Pfizer, RAPT, Regeneron, Revolution Medicines, Sanofi, Takeda, Yuhan; Researcher – Abbvie, Alkermes, AstraZeneca, Elevation Oncology, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma, RAPT, Turning Point Therapeutics.
Remaining Faculty Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer: has disclosed no financial relationships.
Michele Bielarski, RN, Nurse Reviewer: has disclosed no financial relationships.
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer): has disclosed no financial relationships.
Dorothy Duffy, RPh (planner/reviewer): has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.
AKH and Clinical CME Group, LLC, Staff and Planners have no financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with “Opt Out” in the subject line.
